Prostate cancer
NEW --- Treatment selection in mCRPC patients harbouring HRR gene mutations

Fernand (73 years old)

Fernand, 73 years old, goes to his grandson’s volleyball games every week. As it hurts for him to sit in the stand, they provide a more comfortable seat for him. He was diagnosed with PCa 7 years ago.

Medical history:

  • 7 years ago: RP for PCa (pT3bN0, ISUP grade 5, postoperative PSA <0.1 ng/ml)
  • 6 years ago: salvage RT for rising PSA (0.53 ng/ml)
  • 5 years ago: ADT started because of rising PSA (7 ng/ml), no metastases on conventional imaging
  • 2 years ago: progression to mCRPC (bone), 1st-line treatment with abiraterone, 2nd-line treatment with 6 cycles docetaxel

Current situation:

  • Rising PSA: from 0.9 ng/ml to 3.9 ng/ml
  • ECOG PS: 1
  • Back pain
  • MRI spine:
    • Progression of existing bone lesions and new bone lesions in multiple vertebrae
    • Enlarging soft tissue component at Th9 causing spinal cord compression
    • Neurosurgical decompression was performed
    • Histology from neurosurgical decompression: metastatic poorly-differentiated PCa
  • Somatic ATM mutation

Which of the following treatment options would you choose for this patient?